Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Genentech has agreed to buy Jecure Therapeutics for an undisclosed sum. San Diego–based Jecure came out of stealth last year with $20 million from Versant Ventures to develop small molecules for nonalcoholic steatohepatitis (NASH), a serious liver disease. The deal gives Genentech a portfolio of early-stage compounds that block NLRP3, an immunomodulatory protein that helps trigger cellular inflammatory responses. In addition to NASH, NLRP3 inhibitors could be relevant in gout, inflammatory bowel disease, and cardiovascular diseases.
This article has been sent to the following recipient: